I think that slide 4 of the presentation helps a little.
It outlines the 4 reasons of why there was no revenue growth in 2018 and what they plan to do in 2019 to get back on track.
Slide 13 provides some emphasis that things are improving.
I think that the business will recover revenue and that it will continue to grow.
It is a great business with a good moat.
HT1
- Forums
- ASX - By Stock
- IRI
- Ann: Results Briefing FY2018
Ann: Results Briefing FY2018, page-5
Featured News
Add IRI (ASX) to my watchlist
(20min delay)
|
|||||
Last
62.5¢ |
Change
0.035(5.93%) |
Mkt cap ! $110.8M |
Open | High | Low | Value | Volume |
59.0¢ | 64.0¢ | 59.0¢ | $171.6K | 280.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 34900 | 61.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
65.0¢ | 13000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 34900 | 0.610 |
2 | 13041 | 0.595 |
4 | 30089 | 0.590 |
3 | 69326 | 0.585 |
2 | 6700 | 0.580 |
Price($) | Vol. | No. |
---|---|---|
0.650 | 13000 | 3 |
0.660 | 765 | 1 |
0.665 | 1503 | 1 |
0.680 | 36505 | 2 |
0.690 | 1380 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
IRI (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online